These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Molecular mechanisms and therapeutic development of angiogenesis inhibitors. Cao Y Adv Cancer Res; 2008; 100():113-31. PubMed ID: 18620094 [TBL] [Abstract][Full Text] [Related]
6. Thalidomide: dual benefits in palliative medicine and oncology. Davis MP; Dickerson ED Am J Hosp Palliat Care; 2001; 18(5):347-51. PubMed ID: 11565189 [TBL] [Abstract][Full Text] [Related]
7. Chapter 6. Mouse models to investigate anti-cancer effects of VEGF inhibitors. Crawford Y; Ferrara N Methods Enzymol; 2008; 445():125-39. PubMed ID: 19022058 [TBL] [Abstract][Full Text] [Related]
8. Targeting vessel abnormalization in cancer. Garber K J Natl Cancer Inst; 2007 Jul; 99(13):991-2, 995. PubMed ID: 17596567 [No Abstract] [Full Text] [Related]
9. Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed. ten Hagen TL; Seynhaeve AL; Eggermont AM Immunol Rev; 2008 Apr; 222():299-315. PubMed ID: 18364010 [TBL] [Abstract][Full Text] [Related]
10. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Shojaei F; Ferrara N Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057 [TBL] [Abstract][Full Text] [Related]
11. [Inhibition of the VEGF receptor system with tyrosine kinase inhibitors. Angiogenesis inhibition in oncology]. Mross K Pharm Unserer Zeit; 2008; 37(5):404-15. PubMed ID: 18729270 [No Abstract] [Full Text] [Related]
12. [Neoplasms under control with the help of vascular treatment?]. Laurén J; Alitalo K Duodecim; 2000; 116(7):705-11. PubMed ID: 12078136 [No Abstract] [Full Text] [Related]
13. [Angiogenesis: all a radiation oncologist should know]. Mazeron R; Bourhis J; Deutsch E Cancer Radiother; 2008 Jan; 12(1):50-60. PubMed ID: 18243753 [TBL] [Abstract][Full Text] [Related]